CogniC

**CogniC** is NeuroSense's investigational oral fixed-dose combination therapy for Alzheimer's disease. NeuroSense describes it as a multi-pathway approach intended to address neuroinflammation, oxidative stress, amyloid-beta aggregation, microRNA dysregulation, lysosomal dysfunction, and impaired autophagy. Public trial and company materials associate the CogniC Alzheimer's program with the same ciprofloxacin + celecoxib combination subsequently referred to as **PrimeC**; the RoAD Phase 2 study evaluated this combination in mild-to-moderate Alzheimer's disease. ([neurosense-tx.com](https://www.neurosense-tx.com/research-development/))

Other names

celecoxib + ciprofloxacinciprofloxacin + celecoxib